Investment Thesis
AVITA Medical exhibits severe financial distress with negative stockholders' equity of -$16.6M, negative operating cash flow of -$31.2M, and liabilities exceeding assets by $16.6M. Despite strong gross margins of 82.1%, the company burns cash rapidly with operating losses of -$42.5M on just $71.6M in revenue, indicating fundamental business model challenges that extend beyond product-level economics.
Strengths
- Exceptional gross margin of 82.1% demonstrates strong product pricing power and production efficiency
- Modest revenue growth of 1.0% YoY shows market traction despite operational challenges
- Zero long-term debt provides flexibility and eliminates refinancing risk in near term
Risks
- Negative stockholders' equity of -$16.6M indicates technical insolvency and heightened bankruptcy risk
- Severe cash burn of -$31.2M in operating cash flow with only $10.2M cash on hand provides minimal runway
- Operating margin of -59.4% and net margin of -67.8% reveal massive operating losses that far exceed revenue generation capacity
- Current ratio of 0.57x indicates immediate liquidity crisis with liabilities exceeding current assets
- Free cash flow of -$32.2M demonstrates the company is not self-sustaining and dependent on external financing
Key Metrics to Watch
- Cash runway and timeline to funding crisis given current burn rate
- Path to operating profitability and achievement of positive operating cash flow
- Revenue growth acceleration and ability to scale without proportional cost increases
- Stockholders' equity recovery and return to positive net worth
Financial Metrics
Revenue
71.6M
Net Income
-48.6M
EPS (Diluted)
$-1.74
Free Cash Flow
-32.2M
Total Assets
56.4M
Cash
10.2M
Profitability Ratios
Gross Margin
82.1%
Operating Margin
-59.4%
Net Margin
-67.8%
ROE
N/A
ROA
-86.2%
FCF Margin
-45.0%
Balance Sheet & Liquidity
Current Ratio
0.57x
Quick Ratio
0.46x
Debt/Equity
N/A
Debt/Assets
129.5%
Interest Coverage
-8.50x
Long-term Debt
0.0
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-20T11:12:12.543643 |
Data as of: 2025-12-31 |
Powered by Claude AI